Gene · 2621
Papers3,604
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 3,604
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Multi-omics Approaches to CCAAT/Enhancer-Binding Protein Beta in Oral Squamous Cell Carcinoma: Crosstalk Between Tumor Cells and Tumor-Associated Macrophages Driving Disease Progression. | Curr Cancer Drug Targets | 2026 | 40976901 | PubTator, text mining | PubMed |
| Phytochemicals as potential AXL inhibitors for cancer therapy: A computational study. | Comput Biol Chem | 2026 | 40845692 | PubTator, text mining | PubMed |
| Electrochemical immunosensing for rapid glaucoma disease diagnosis through simultaneous determination of SPP1 and GAS6 proteins in ocular fluids. | Talanta | 2026 | 40494269 | PubTator, text mining | PubMed |
| Immunomodulatory therapy for sepsis: from pathophysiological mechanisms to precision treatment. | Front Cell Infect Microbiol | 2025 | 41756408 | PubTator, text mining | PubMed |
| Warfarin and bevacizumab suppress tumor progression in pancreatic ductal adenocarcinoma by targeting EGFR-PI3K-Akt signaling: inhibition of proliferation/migration and apoptosis induction. | Transl Cancer Res | 2025 | 41510069 | PubTator, text mining | PubMed |
| SB431542, a Selective Inhibitor of the TGF-β Type I Receptor, Enhances Doxorubicin Antitumor Activity via p63 Activation in Mutant p53 Breast Cancer Cells. | Front Biosci (Landmark Ed) | 2025 | 41504053 | PubTator, text mining | PubMed |
| Single-Cell Multi-Omics Reveals B2M-Mediated Myeloid Reprogramming and Constructs a Predictive Model for Early Hepatocellular Carcinoma Recurrence. | FASEB J | 2025 | 41427790 | PubTator, text mining | PubMed |
| DENetwork unveils non-differentially expressed genes with functional relevance across conditions through information flow perturbation. | Nucleic Acids Res | 2025 | 41404797 | PubTator, text mining | PubMed |
| A fast-progressing orthotopic ovarian cancer model reveals synergistic antitumor effects of AXL-targeting nanobodies and Olaparib. | Gynecol Oncol Rep | 2025 | 41404332 | PubTator, text mining | PubMed |
Profile of GAS6 gene single nucleotide polymorphisms [GAS6 c.834+7G>A (rs8191974), and GAS6 c.1332C>T (rs1803628)] among a cohort of Egyptian women with preeclampsia: Relation to disease risk and severity. | J Genet Eng Biotechnol | 2025 | 41386823 | PubTator, text mining | PubMed |
| HMGA1/SMAD3 Promoter Complex Mediates PD-L1-Dependent Transcriptional Regulation of GAS6, EGR1 and PD-L1. | Front Biosci (Landmark Ed) | 2025 | 41351417 | PubTator, text mining | PubMed |
| Human oligodendrocyte progenitor cells mediate synapse elimination through TAM receptor activation. | Nat Commun | 2025 | 41350273 | PubTator, text mining | PubMed |
| HIV-associated non-Hodgkin lymphoma tumor-microenvironment axes differ by EBV status across cellular origins. | bioRxiv | 2025 | 41279969 | PubTator, text mining | PubMed |
| At the intersection of immunology and oncology: TAM receptors in the regulation of immune responses and tumorigenesis-related processes | Postepy Biochem | 2025 | 41263792 | PubTator, text mining | PubMed |
| Dalbergia odorifera T.C. Chen leaf extract promotes microglial energy expenditure to phagocytize neutrophils after cerebral ischemia-reperfusion. | Phytomedicine | 2025 | 41253024 | PubTator, text mining | PubMed |
| Correction: GAS6/AXL signaling promotes M2 microglia efferocytosis to alleviate neuroinflammation in sepsis-associated encephalopathy. | Cell Death Discov | 2025 | 41249145 | PubTator, text mining | PubMed |
| Association of GAS6, AXL, and GAS6-AS lncRNAs with nephropathy in Egyptian patients with type 2 diabetes mellitus: a case-control observational study. | Nutr Diabetes | 2025 | 41233312 | PubTator, text mining | PubMed |
| Modifications of the Secretome of Mesenchymal Stromal Cells under Conditions of Stress-Induced Aging. | Bull Exp Biol Med | 2025 | 41196481 | PubTator, text mining | PubMed |
| Evaluation of TAM Receptor Targeting in Pathophysiology of Idiopathic Pulmonary Fibrosis. | Medicina (Kaunas) | 2025 | 41155824 | PubTator, text mining | PubMed |
| Targeted Therapies Modulating Mesenchymal-Epithelial Transition-Linked Oncogenic Signaling in the Tumor Microenvironment: Comparative Profiling of Capmatinib, Bemcentinib, and Galunisertib. | J Clin Med | 2025 | 41095933 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2621/papers?page=6